ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Quarterly Earnings Results

by · The Cerbat Gem

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.14 by $0.12, Zacks reports. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. ACADIA Pharmaceuticals updated its FY 2025 guidance to EPS.

ACADIA Pharmaceuticals Stock Up 2.2%

Shares of NASDAQ ACAD traded up $0.48 during mid-day trading on Wednesday, hitting $22.33. 2,336,738 shares of the company were exchanged, compared to its average volume of 2,161,079. The stock has a 50 day simple moving average of $22.87 and a 200-day simple moving average of $21.83. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $26.65. The firm has a market cap of $3.77 billion, a price-to-earnings ratio of 16.79, a price-to-earnings-growth ratio of 7.90 and a beta of 0.75.

Analyst Ratings Changes

Several research firms have recently weighed in on ACAD. Royal Bank Of Canada increased their price objective on ACADIA Pharmaceuticals from $39.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. JPMorgan Chase & Co. decreased their price objective on ACADIA Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Monday, September 29th. Needham & Company LLC decreased their price objective on ACADIA Pharmaceuticals from $30.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, September 24th. JMP Securities increased their price objective on ACADIA Pharmaceuticals from $37.00 to $38.00 and gave the company a “market outperform” rating in a report on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft set a $29.00 price objective on ACADIA Pharmaceuticals in a report on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.33.

View Our Latest Stock Analysis on ACAD

Insider Buying and Selling at ACADIA Pharmaceuticals

In related news, EVP Mark C. Schneyer sold 3,498 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $23.65, for a total transaction of $82,727.70. Following the completion of the sale, the executive vice president directly owned 43,447 shares of the company’s stock, valued at $1,027,521.55. This trade represents a 7.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Elizabeth A. Garofalo sold 1,600 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $25.98, for a total value of $41,568.00. Following the completion of the sale, the director directly owned 25,382 shares of the company’s stock, valued at approximately $659,424.36. This trade represents a 5.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 27,098 shares of company stock valued at $678,256. Corporate insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Empowered Funds LLC purchased a new stake in ACADIA Pharmaceuticals during the 1st quarter worth about $186,000. Cetera Investment Advisers grew its holdings in ACADIA Pharmaceuticals by 7.9% in the 2nd quarter. Cetera Investment Advisers now owns 12,763 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 931 shares during the period. FORA Capital LLC acquired a new position in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at about $297,000. Tower Research Capital LLC TRC lifted its stake in shares of ACADIA Pharmaceuticals by 250.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 15,629 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 11,171 shares in the last quarter. Finally, Amundi acquired a new position in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at about $433,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

(Get Free Report)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

Featured Stories